← Eichor
Study identifier: NCT06862739 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination

Condition: Diabetes Mellitus · Type 2 DM  ·  Sponsor: Nabiqasim Industries (Pvt) Ltd

PhasePhase 4
Planned participants800
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

The efficacy and safety of a triple-pill combination therapy for advanced type 2 diabetes care. The study aims to assess the impact of 3 Oral Anti Diabetic (OAD) drugs on metabolic control, patient compliance, weight management, quality of life, diabetic treatment satisfaction and frequency of hypoglycemic events by combining them into a fixed-dose single pill.

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (2)

Faisalabad clinicsFaisalabad, Punjab Province, PakistanRecruiting
Aap ka ClinicLahore, Punjab Province, PakistanRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06862739